"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Jazz Pharmaceuticals Inc.","Jazz Pharmaceuticals","$20,000,000","$0","$20,000,000","2007","20070713","healthcare-related offenses","off-label or unapproved promotion of medical products","False Claims Act and related","Jazz Pharmaceuticals, Inc. agreed to pay $20 million in penalties and victim compensation to resolve parallel criminal and civil investigations relating to the illegal marketing practices of its wholly-owned subsidiary Orphan Medical, Inc. Jazz was offered a non-prosecution agreement while Orphan pleaded guilty to felony misbranding, in violation of the Food, Drug, and Cosmetic Act in connection with its illegal promotion of the prescription medication Xyrem.","federal","agency action","U.S. Attorney-Eastern District of New York","civil and criminal","plea & non-prosecution agreement","","","","","","","","","","","Ireland","","publicly traded","JAZZ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/usao/nye/pr/2007/2007jul13a.html",""
"Jazz Pharmaceuticals plc","Jazz Pharmaceuticals","$57,000,000","$0","$57,000,000","2019","20190404","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","Three pharmaceutical companies -- Jazz Pharmaceuticals plc, Lundbeck LLC, and Alexion Pharmaceuticals Inc. -- agreed to pay a total of $122.6 million to resolve allegations that they each violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical Program (ChampVA) copays for their own products, through purportedly independent foundations that the companies used as mere conduits.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","Ireland","","publicly traded","JAZZ","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/three-pharmaceutical-companies-agree-pay-total-over-122-million-resolve-allegations-they-paid",""
